Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
BIBiogen Inc. logo

Biogen Inc. (BIIB)

NASDAQ Global Select · Currency in USD
$250.69 ▼ -3.15 (-1.24%)
At close: Oct 23, 4:00 PM ET. Market closed.
$246.01 ▼ -4.68 (-1.87%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$253.84
Open
$251.68
Day's Range
$246.15 – $252.44
52 Week Range
$138.00 – $254.41
Volume
1,157,287
Avg. Volume
1,155,969
Market Cap
$37.04B
Beta (5Y Monthly)
0.17
PE Ratio (TTM)
44.14
EPS (TTM)
$5.65
Earnings Date
Oct 28, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$245.63

Profile: Biogen Inc.

Sector
Healthcare
Industry
Drug Manufacturers - General
Full-time employees
7,500
CEO
Christopher A. Viehbacher
Website
biogen.com

Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis.

Earnings

Next report: Wed, Oct 28, 2026
EPS estimate $1.97 · Revenue est. $2.63B
DateEst.Actual
Jul 29, 2026$2.94$3.60Beat
Apr 29, 2026$3.05$3.57Beat
Feb 6, 2026$1.63$1.99Beat
Oct 30, 2025$3.88$4.81Beat
Jul 31, 2025$3.90$5.47Beat
May 1, 2025$2.90$3.02Beat

Analyst view

Consensus price target
$245.63 ▼ -2.0%
Range $175.00 – $300.00
Rating: Buy
Buy 65% · Hold 33% · Sell 2%

Get free alerts on BIIB and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.